STOCK TITAN

Nanox Signs Commercial Agreement with Howard Technology Solutions to Deploy 300 Nanox.ARC Systems Across U.S. Over Three Years

(Positive)
Tags

Nano-X Imaging (NASDAQ:NNOX) signed a commercial agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years, including 60 systems in year one. The Nanox.ARC is an FDA-cleared multisource digital tomosynthesis system said to offer 3D imaging at lower cost and reduced radiation versus traditional CT.

Howard will market and deploy systems across its national healthcare and public sector channels, targeting underserved customer segments and leveraging its nationwide sales and service infrastructure.

Loading...
Loading translation...

Positive

  • Agreement to deploy 300 Nanox.ARC systems over three years
  • 60 systems scheduled for deployment in year one
  • Expands U.S. channel via Howard's national healthcare and public sector footprint

Negative

  • None.

News Market Reaction – NNOX

-24.39% 4.7x vol
37 alerts
-24.39% Session close to close
+2.7% Peak Tracked
-28.5% Trough Tracked
$198.33M Market Cap
4.7x Rel. Volume

In the Apr 20 session, NNOX declined 24.39%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.7% during that session. Argus tracked a trough of -28.5% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.7x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -24.4% in the session following this news. A negative reaction despite a sizable U...
Analysis

The stock dropped -24.4% in the session following this news. A negative reaction despite a sizable U.S. rollout plan would fit a pattern where investors refocus on fundamentals after initial enthusiasm. The Howard agreement targets 300 systems, but many previously contracted Capex systems have not yet generated revenue, and 2025 net loss reached $75.0 million. An unused F-3/A shelf also frames ongoing capital flexibility, so concerns around execution and funding could weigh on sentiment.

Key Figures

Planned Nanox.ARC deployments: 300 systems Year 1 Nanox.ARC units: 60 systems Q4 2025 revenue: $3.7 million +5 more
8 metrics
Planned Nanox.ARC deployments 300 systems To be marketed and deployed by Howard Technology Solutions over three years
Year 1 Nanox.ARC units 60 systems Target deployments in the first year under the Howard agreement
Q4 2025 revenue $3.7 million Quarterly revenue, up from $3.0 million year over year
Q4 2025 GAAP net loss $33.4 million Quarterly net loss, higher than $14.1 million a year earlier
Non-cash impairment $17.5 million Impairment linked to restructuring Korean chip manufacturing line
Full-year 2025 revenue $13.0 million Company-wide revenue for 2025
Full-year 2025 net loss $75.0 million Net loss for 2025
Cash and securities $60.0 million Cash, deposits and marketable securities as of December 31, 2025

Historical Context

5 past events · Latest: Apr 16 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Apr 16 Design award win Positive +4.6% Nanox.ARC X wins 2026 Red Dot Product Design award for compact 3D system.
Apr 14 Clinical collaboration Positive +3.8% Meir Medical Center study to evaluate Nanox.ARC vs X-ray and CT for fractures.
Apr 13 U.S. distribution deal Positive +4.8% Distribution agreement with DXI to deploy Nanox.ARC across Arkansas network.
Apr 06 Earnings date notice Neutral -3.0% Announcement of timing for Q4 2025 results and business update call.
Apr 02 U.S. distribution deal Positive +0.0% Integrity Medical Service pact targeting initial Nanox.ARC deployments in four states.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive operational updates (design award, clinical collaboration, distribution deals) often coincided with positive 24h price reactions, suggesting news sensitivity to commercial and product milestones.

Recent Company History

Over the last few weeks, Nanox has announced multiple Nanox.ARC-related milestones, including a U.S. distribution deal with Integrity Medical Service targeting 4 systems in Year 1 and 12 in Year 2, a regional agreement in Arkansas, and a clinical collaboration with Meir Medical Center. The Nanox.ARC X system also received a Red Dot Product Design 2026 award. An earnings-date notice on April 6, 2026 drew a minor negative reaction, contrasting with generally positive responses to commercial and product news.

Key Terms

digital tomosynthesis, fda-cleared
2 terms
digital tomosynthesis medical
"an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible"
A medical imaging method that takes multiple low-dose X-ray pictures from different angles and combines them into thin 'slices' of a body part, like slicing a loaf of bread to see interior layers rather than one flat cut. For investors, it matters because the technology can improve diagnostic accuracy and workflow in hospitals and clinics, influencing device sales, reimbursement decisions, competitive positioning, and the pace at which healthcare providers adopt new equipment.
fda-cleared regulatory
"the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system"
FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Howard’s nationwide reach across healthcare and public sector markets expands Nanox’s U.S. channel partner network to additional customer segments

PETAH TIKVA, Israel, April 20, 2026 -- Nano-X Imaging Ltd. (“Nanox”, or the “Company”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a strategic commercial agreement with Howard Technology Solutions, a leading U.S.-based technology solutions provider with deep expertise in healthcare and a broad national footprint.

The agreement will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings, at a lower cost and reduced radiation dose compared to traditional CT.

Under the terms of the agreement, Howard Technology Solutions will market and deploy 300 Nanox.ARC systems over a three-year period, 60 for the first year, and introduce the system to healthcare facilities and public sector customers across its national network.

“We are pleased to welcome Howard Technology Solutions as our newest U.S. distribution partner,” commented Erez Meltzer, CEO and Acting Chairman of Nanox. “Howard's national reach and established presence in healthcare and public sector markets give us a scalable framework for expanding Nanox.ARC deployments. This agreement reflects our confidence in the commercial demand for the Nanox.ARC and our ability to engage partners that can support sustained growth in system placements across the U.S.”

“The Nanox.ARC is unlike anything currently in our portfolio, bringing advanced 3D imaging to facilities that haven't previously had access to this kind of diagnostic capability,” said Frank Blanco, Vice President of Purchasing, of Howard Technology Solutions. “We see strong potential across our healthcare and public sector customer base, and our nationwide deployment infrastructure is well-suited to support Nanox's commercial rollout at scale.”

Howard Technology Solutions, a division of Howard Industries, provides technology procurement, deployment, and support services to healthcare facilities, government agencies, and public sector organizations across the U.S. It enables the deployment and support of clinical technologies for its complementary line of healthcare technology products, including point-of-care, medication carts, workstation-on-wheels, telehealth solutions, and computer hardware.

The company's national sales and service infrastructure, combined with its established relationships in markets that have traditionally been underserved by medical imaging distributors, positions it well to introduce the Nanox.ARC to new customer segments.

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision

About Howard Technology Solutions

Howard Technology Solutions’ Medical Division is a premier manufacturer and provider of healthcare technology, specializing in point-of-care (POC) medication carts, workstation-on-wheels, telehealth solutions, and computer hardware serving hospitals and clinics throughout the U.S. 

Founded in 2003, they serve hospitals and clinics by producing durable, U.S.-assembled equipment designed to improve patient care and clinician efficiency.

In addition to these products, Howard provides specialized services including on-site setup, installation, and, in some cases, tailored technology training.

From our own Howard manufactured products, such as desktops, notebooks, servers, kiosks, and medical carts to partner products from other leading technology innovators, such as Lenovo, HP, and Microsoft, you can be sure when you buy from Howard that you are getting the most for your technology dollars. For more information, please visit https://howard.com/index.cfm

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com


FAQ

What did Nano-X (NNOX) announce on April 20, 2026 about Howard Technology Solutions?

Nano-X announced a commercial agreement with Howard to deploy 300 Nanox.ARC systems over three years. According to the company, Howard will market and deploy 60 systems in year one and introduce the system across its national healthcare and public sector channels.

How many Nanox.ARC systems will Howard deploy for Nano-X (NNOX) in year one?

Howard will deploy 60 Nanox.ARC systems in the first year of the agreement. According to the company, the 60-unit first-year target is part of a broader three-year plan totaling 300 systems across the U.S.

Does the Nanox.ARC have FDA clearance as mentioned in the NNOX announcement?

Yes. The Nanox.ARC is described as an FDA-cleared multisource digital tomosynthesis system. According to the company, it enables 3D imaging with lower cost and reduced radiation versus traditional CT in more clinical settings.

What is the timeline and total scope of the Howard distribution agreement for Nano-X (NNOX)?

The agreement covers a three-year commercial rollout to deploy 300 Nanox.ARC systems in the U.S. According to the company, deployments start immediately with a 60-unit target in year one and continue through year three to reach 300 systems.

How will Howard Technology Solutions support Nano-X (NNOX) commercial rollout nationally?

Howard will market, deploy, and support Nanox.ARC systems across its healthcare and public sector network. According to the company, Howard's national sales and service infrastructure and existing customer relationships enable scaled deployments to underserved markets.

What does the 300-unit agreement mean for Nano-X (NNOX) market access in the U.S.?

The deal broadens Nano-X's U.S. channel reach into healthcare and public sector segments via Howard's footprint. According to the company, this partnership aims to introduce Nanox.ARC to traditionally underserved facilities and expand system placements nationwide.